目的 探究贝伐珠单抗联合FOLFOX标准化疗治疗结直肠癌寡转移术后患者的效果及对中位无进展生存期（mPFS）的影响。 方法 回顾性收集2021年1月至2024年6月阜阳市人民医院收治的结直肠癌寡转移术后患者的临床资料，依据术后所接受的治疗方案分为联合组（贝伐珠单抗联合FOLFOX标准化疗，n = 30）与化疗组（FOLFOX标准化疗，n = 72），均完成6个周期（21 d为1个周期）治疗，统计并比较两组治疗效果、治疗前后血清标志物水平［癌胚抗原（CEA）、糖类抗原199（CA199）、血小板计数/淋巴细胞计数比值（PLR）、淋巴细胞计数/单核细胞计数比值（LMR）、C反应蛋白/白蛋白比值（CRP/ALB）］、毒副反应，比较随访生存结局（每3个月随访1次，随访截止时间为2025年11月1日），分析血清标志物与结直肠癌寡转移术后患者生存预后的相关性，并展开Cox回归分析筛选结直肠癌寡转移患者预后影响因素。 结果 联合组整体疗效等级优于化疗组，疾病控制率（DCR）高于化疗组（P < 0.05）；治疗后，联合组血清CEA、CA199、PLR、CRP/ALB低于同组治疗前及化疗组治疗后（P < 0.05），LMR高于同组治疗前及化疗组治疗后（P < 0.05），两组毒副反应发生率差异无统计学意义（P > 0.05）；随访截止，联合组平均PFS及mPFS、平均生存时间（OS）及中位OS均长于化疗组（P < 0.05）；102例患者按生存预后分为进展组（进展或肿瘤相关死亡，n = 62）与无进展组（随访存活，n = 40），进展组治疗结束血CEA、CA199、PLR、CRP/ALB高于无进展组，LMR低于无进展组（P < 0.05）；结直肠癌寡转移患者治疗结束血清CEA、CA199、PLR、CRP/ALB与mPFS、中位OS均呈负相关，LMR与mPFS、中位OS均呈正相关（P < 0.05）；Cox回归分析显示，高CEA、高CRP/ALB为结直肠癌寡转移患者预后的独立危险因素（P < 0.05），贝伐珠单抗+ FOLFOX化疗和高LMR水平为保护因素（P < 0.05）。 结论 贝伐珠单抗联合FOLFOX标准化疗较单独化疗可提高结直肠癌寡转移术后患者疾病控制率、降低肿瘤相关因子表达水平，且生存预后更好，不良反应可控。

Objective To explore the efficacy of bevacizumab in combination with FOLFOX standard chemotherapy for the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on the median progression-free survival （mPFS）. Methods The clinical data of postoperative patients with oligometastatic colorectal cancer admitted to Fuyang People's Hospital from January 2021 to June 2024 were retrospectively collected. Based on the treatment regimens received after surgery， the patients were divided into the combination group （bevacizumab + FOLFOX standard chemotherapy， n = 30） and the chemotherapy group （FOLFOX standard chemotherapy， n = 72）. All patients completed 6 cycles of treatment （with 21 days as 1 cycle）. The therapeutic effects， serum marker levels before and after treatment ［carcinoembryonic antigen （CEA）， carbohydrate antigen 199 （CA199）， platelet count/lymphocyte count ratio （PLR）， lymphocyte count/monocyte count ratio （LMR）， C-reactive protein/albumin ratio （CRP/ALB）］， and toxic and side effects of the two groups were systematically counted， analyzed， and compared. The follow-up survival outcomes were compared （with follow-up conducted once every 3 months until November 1， 2025）. Additionally， the correlation between serum markers and the survival prognosis of patients was analyzed， and Cox regression analysis was employed to screen the prognostic factors of patients. Results The overall efficacy grade of the combined group was superior to that of the chemotherapy group， and the disease control rate （DCR） was higher （P < 0.05）. After treatment， the levels of serum CEA， CA199， PLR， and CRP/ALB in the combined group were lower than those before treatment within the same group and those after treatment in the chemotherapy group （P < 0.05）， whereas the LMR was higher （P < 0.05）. There was no statistically significant difference in the incidence of toxic and side effects between the two groups （P > 0.05）. At the end of the follow-up， the combined group exhibited longer average progression-free survival （PFS）， median PFS （mPFS）， average overall survival （OS）， and median OS （P < 0.05）. A total of 102 patients were classified into the progression group （progression or tumor-related death， n = 62） and the non-progression group （surviving during follow-up， n = 40） based on survival prognosis. At the end of treatment， the levels of serum CEA， CA199， PLR， and CRP/ALB in the progression group were higher than those in the non-progression group， while the LMR was lower （P < 0.05）. At the end of treatment for patients with oligometastatic colorectal cancer， serum CEA， CA199， PLR， and CRP/ALB were negatively correlated with mPFS and median OS， whereas LMR was positively correlated with mPFS and median OS （P < 0.05）. Cox regression analysis indicated that high CEA and high CRP/ALB were independent risk factors for the prognosis of patients with oligometastatic colorectal cancer （P < 0.05）， while bevacizumab + FOLFOX chemotherapy and high LMR level were protective factors （P < 0.05）. Conclusions Bevacizumab combined with FOLFOX standard chemotherapy can enhance the disease control rate among postoperative patients with oligometastatic colorectal cancer， decrease the expression level of tumor-related factors， and offer a better survival prognosis with controllable adverse reactions when compared with chemotherapy alone.